WO2019175900A1 - Purification of neisseria meningitidis polysaccharides - Google Patents
Purification of neisseria meningitidis polysaccharides Download PDFInfo
- Publication number
- WO2019175900A1 WO2019175900A1 PCT/IN2019/050208 IN2019050208W WO2019175900A1 WO 2019175900 A1 WO2019175900 A1 WO 2019175900A1 IN 2019050208 W IN2019050208 W IN 2019050208W WO 2019175900 A1 WO2019175900 A1 WO 2019175900A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- men
- purification
- concentrate
- polysaccharide
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
Definitions
- the present invention relates to a process of purification of bacterial polysaccharide.
- the present invention particularly relates to purification process for purification of Neisseria meningitidis serogroup C, W and Y polysaccharides.
- the N. meningitidis polysaccharides of the present invention are capable of being used in the production of polysaccharide and polysaccharide-protein conjugate vaccine(s) against meningococcal infections.
- Polysaccharides are used in preparation of vaccines.
- Monovalent, bivalent and poly (multi) valent vaccines containing one, two or more polysaccharides and their conjugates are available in the market for prevention of certain diseases or infections caused by various microorganisms such as Streptococcus pneumoniae, Haemophilus influenzae and N. meningitidis and have proved valuable in preventing the respective diseases to a significant extent.
- Surveillance data gathered in the years following the introduction of the vaccine Prevenar has clearly demonstrated a reduction of invasive pneumococcal disease in US infants as expected.
- a need for improving yields as well as quality (purity) of the polysaccharides always exist in the industry as evidenced by the continuing research.
- N. meningitidis capsular polysaccharides The production of purified N. meningitidis capsular polysaccharides is the foremost requirement for an effective conjugation with the carrier protein and its development as a conjugate vaccine.
- the cost for the cultivation of N. meningitidis and the purification of polysaccharides is generally high and involves long working hours since it involves a series of production and purification steps.
- Patent application no. US2009/ 0182128 Al, Paolo Costantino et al relates to purification of Men W, A, and Y using CTAB and ethanol treatment (50% - 95%) and use of CaCh and carbon filtration.
- the disclosed patent application uses multiple steps for the purification of crude polysaccharides and long hours for the purification process.
- the present invention discloses process that has been optimized to enable the purification of N. meningitidis serogroups in lesser time without requiring chromatography.
- the main object of the present invention is to provide a process of purification of bacterial polysaccharide.
- Another object of the present invention is to provide a process of purification of Neisseria meningitidis serogroup C, W and Y polysaccharides.
- the present invention describes a rapid, industrially scalable, cost effective process for the purification of Neisseria meningitidis polysaccharides.
- the said process provides a purification method for purifying N. meningitidis serogroup C, W and Y polysaccharide at a significantly reduced time.
- the purification process does not require any chromatography step thereby making the invention rapid and cost effective.
- the process of the present invention commences with collecting the fermentation broth after centrifugation of inactivated bacterial fermenter culture, diafiltration of said fermentation broth to obtain concentrated fermentation broth, adjusting pH of said concentrated fermentation broth to desired level, regular intermittent stirring of said concentrated fermentation broth of desired pH at pre-determined temperature for pre- determined time and thereafter diafiltration of the solution is carried out with specific reagents to obtain partially purified polysaccharide.
- the partially purified polysaccharide so obtained is mixed with specific buffers and chemical reagents and the resultant solution is incubated at specific temperature for pre-determined duration with intermittent stirring at regular intervals. Ethanol treatment of the incubated solution thus obtained is carried out at specific temperature for pre-determined duration with intermittent stirring at regular intervals along with or after incubation with the earlier reagents.
- the supernatant of the ethanol treated solution is separated and diafiltered with specific reagents.
- the diafiltered solution is then carbon filtered using carbon filter of predefined specifications until optimum optical density of the solution is achieved.
- the solution is then concentrated at desired level and filtered and stored at temperature less than 0° C.
- the process of purification of present invention is completed in less than 11 hours. The process is rapid, cost effective, entirely scalable and purified polysaccharides meet the desired specifications with better yields.
- Figure-1 Depicts the NMR spectrum of Men
- Figure-2 Depicts the NMR spectrum of Men
- FIG. 1 Depicts the HPLC Chromatogram of Men C
- Figure-5 Depicts the HPLC Chromatogram of Men Y
- FIG. 1 Depicts the HPLC Chromatogram of Men W
- the present invention describes the purification method of Bacterial polysaccharides (PS) specifically the polysaccharides of Neisseria meningitidis.
- PS Bacterial polysaccharides
- the essence of the invention is the rapid and cost- effective purification process of Men C ,, Men W and Men Y of Neisseria meningitidis.
- Bacterial polysaccharides are used in the preparation of vaccines against many fatal diseases and infections.
- PS vaccine preparation requires purified polysaccharides free from salts or solvents containing proteins, peptides, nucleic acids, and other biomolecules to enhance their sensitivity.
- the invention discloses the method that has been optimized to enable the purification of MenC, MenW and Men Y polysaccharide at reduced time.
- Neisseria meningitidis strain from which the PS is to be extracted is inoculated in the flask and subsequently in fermenter containing appropriate media components required for bacterial growth. After achieving the maximum optical density, in the range of 8 to 10 depicting substantial bacterial growth, it is subjected to growth termination by adding prerequisite concentration of formaldehyde and the resultant Fermentation Broth (FB) is obtained.
- the fermented broth as obtained above is used for purifying Men C, Men
- the fermented broth (FB) is concentrated and diafiltered using lOOkDa polyether sulfone membrane (PES) with 10-12 volumes of MilliQ water (MQW) to obtain diafiltered concentrate.
- PES polyether sulfone membrane
- MQW MilliQ water
- the pH of the diafiltered concentrate is adjusted in the range of 13 ⁇ 0.1 after which the resultant PS is incubated at 90°C for 1-2 hrs.
- the incubated diafiltered concentrate of PS is cooled to room temperature , i.e. in the range of 25°C ⁇ 2 using ice bath. After cooling, the incubated PS is again concentrated and diafiltered using lOOkDa polyether sulfone membrane (PES) with 15-20 volumes of MilliQ water to obtain clarified PS concentrate.
- PES polyether sulfone membrane
- TSC tri-sodium citrate
- SS sodium sulfate
- DOC sodium deoxycholate
- ethanol 1.6 ⁇ 0.5 % w/v and 30% ⁇ 5% v/v absolute ethanol
- the concentrated and diafiltered resultant mixture i.e. the partially purified polysaccharide as obtained above is carbon filtered by utilizing Millistak carbon filter to reduce the remaining nucleic acid impurity and to lower down remaining protein impurities.
- water primed millistak POD filters are used for purifying PS from the concentrate.
- Men Y and Men W water primed millistak POD filters with 0.027 m 2 are used while for Men C water primed millistak POD filters
- the partially purified PS is then circulated through the first filter, and OD260nm of the filtrate is noted and recorded. If the OD260nm of the filtrate is less than 0.1, the material is recovered fully by giving a wash of 300-400ml milli Q water (MQW). However, if the OD260nm is greater than
- the material is recirculated for 15mins (30 mins in case of Men C) with masterflex pump speed of 40rpm (90 ⁇ 10 ml/ min flow rate) for both first pass and recirculation. After recirculation, the material is recovered and collected from the first filter, and OD260nm of the filtrate is recorded. If the OD260nm of this filtrate is recorded to be less than 0.1, the material is recovered fully by giving a wash of 300-400ml MQW.
- the first filter is kept aside without flushing, and the collected filtrate is circulated through the second filter with a pump speed of 40rpm and the material is recirculated with a masterflex pump speed of 150-160rpm (420 ⁇ 20 ml/ min flow rate) until the OD260nm is less than 0.1.
- the recirculation time on the second filter is generally between 3-5hrs for Men W PS, whereas for Men Y PS it is 2-3hrs. After the desired O.D. is achieved, the recovered material is kept aside. Both the filters are then joined in series and a wash of 300-600ml was given to recover the bound PS. The wash is mixed with the recovered material.
- Example-1 (MenY and MenW):
- the fermented broth (FB) is concentrated and diafiltered using lOOkDa polyether sulfone membrane (PES) with 10-12 volumes of MilliQ water (MQW). Afterwards, the pH of the partially purified PS is adjusted to 12.5 and then incubated at 90°C for 1.5 hrs. The PS is then cooled to RT (25 ⁇ 2°C).
- PES polyether sulfone membrane
- MQW MilliQ water
- Carbon filtration is performed to reduce nucleic acid and protein impurity load with millistak filter until the OD260 nm reaches below 0.2.
- the collected filtrate is then concentrated by lOOkDa PES followed by 0.2m filtration. The analysis revealed that there is PS loss, therefore the process is not considered for PS purification.
- the fermented broth (FB) is concentrated and diafiltered using lOOkDa polyether sulfone membrane (PES) with 10-12 volumes of MilliQ water (MQW). Afterwards, the pH of the partially purified PS is adjusted to 13 and then incubated at 90°C for 2 hrs. The PS is then cooled to RT (25 ⁇ 2°C). Afterwards, lOOkDa concentration and diafiltration of the crude polysaccharide is performed with 15 volumes of MilliQ water.
- PES polyether sulfone membrane
- MQW MilliQ water
- the fermented broth (FB) is concentrated and diafiltered using lOOkDa polyether sulfone membrane (PES) with 10-12 volumes of MilliQ water (MQW). Afterwards, the pH of the partially purified PS is adjusted to 13 and then incubated at 90°C for 2 hours. The PS is then cooled to RT (25 ⁇ 2°C). Afterwards, lOOkDa concentration and diafiltration of the crude polysaccharide is performed with 15 volumes of MilliQ water.
- PES polyether sulfone membrane
- MQW MilliQ water
- the fermented broth (FB) is concentrated and diafiltered using lOOkDa polyether sulfone membrane (PES) with 10-12 volumes of MilliQ water (MQW). Afterwards, the pH of the partially purified PS is adjusted to 13 and then PS is incubated at 90°C for 2 hrs. The incubated PS is then cooled using ice bath to RT (25 ⁇ 2°C). After cooling, the 100 kDa concentration and diafiltration of the partially purified polysaccharide is performed with 20 volumes of MilliQ water.
- PES polyether sulfone membrane
- MQW MilliQ water
- the partially purified PS is circulated through the first filter, and OD260nm is noted and recorded, if the OD260nm ⁇ 0.2/ more preferably less than 0.1, the material is recovered fully by giving a wash of 300-400ml MQW, however, if the OD260nm >0.2, then the material is recirculated for 15mins, with pump speed of 40rpm (90 ⁇ 10 ml/ min flow rate) for both first pass and recirculation. After 15mins of recirculation, the material is recovered and collected from the first filter, and OD260nm is recorded.
- the material is recovered fully by giving a wash of 300-400ml MQW. If the OD260nm is still >0.2, the first filter is kept aside without flushing, and the collected filtrate is circulated through the second filter with a pump speed as 40rpm and the material is recirculated with a masterflex pump speed as 150-160rpm (420 ⁇ 20 ml/ min flow rate) until the OD260nm reaches ⁇ 0.2/ more preferably less than 0.1. After the desired O.D. is achieved, the recovered material is kept aside. Both the filters are then joined in series and a wash of 300-400ml is given to recover the bound PS.
- the wash is mixed with the recovered material.
- the recirculation time on the second filter is generally between 3-5hrs for Men W PS, whereas for Men Y PS it is 2-3hrs. Recirculation time and pump speed were significant factors to guide the process in terms of reducing nucleic acid and protein load so as to bring the impurity levels well below the specified limits.
- the fermented broth (FB) is concentrated and diafiltered using lOOkDa polyether sulfone membrane (PES) with 10-12 volumes of MilliQ water (MQW). Afterwards, the pH of the partially purified PS is adjusted to 13 and then the PS is incubated at 90°C for 2 hrs. The incubated PS is then cooled using ice bath to RT (25 ⁇ 2°C). Afterwards, 30 kDa concentration and diafiltration of the partially purified polysaccharide is performed with 15 volumes of MilliQ water.
- PES polyether sulfone membrane
- the fermented broth (FB) is concentrated and diafiltered using lOOkDa polyether sulfone membrane (PES) with 10-12 volumes of MilliQ water (MQW). Afterwards, the pH of the partially purified PS is adjusted to 13 and then the PS is incubated at 90°C for 1.5 hrs. The incubated PS was then cooled using ice bath to RT (25 ⁇ 2°C). Afterwards, 30 kDa concentration and diafiltration of the partially purified polysaccharide is performed with 15 volumes of MilliQ water.
- PES polyether sulfone membrane
- MQW MilliQ water
- the fermented broth (FB) is concentrated and diafiltered using lOOkDa polyether sulfone membrane (PES) with 10-12 volumes of MilliQ water (MQW). Afterwards, the pH of the partially purified PS is adjusted to 13 and then the PS is incubated at 90°C for 2 hrs. The incubated PS is then cooled using ice bath to RT (25 ⁇ 2°C). Afterwards, 30 kDa concentration and diafiltration of the crude polysaccharide is performed with 15 volumes of MilliQ water.
- PES polyether sulfone membrane
- the fermented broth (FB) is concentrated and diafiltered using lOOkDa polyether sulfone membrane (PES) with 10-12 volumes of MilliQ water (MQW). Afterwards, the pH of the partially purified PS is adjusted to 13 and then the PS is incubated at 90°C for 2 hrs. The incubated PS is then cooled using ice bath to RT (25 ⁇ 2°C). Afterwards, 30 kDa concentration and diafiltration of the crude polysaccharide is performed with 15 volumes of MilliQ water.
- PES polyether sulfone membrane
- the material is fully recovered by giving a wash of 500-600ml MQW. If the OD260nm was >0.2, then recirculate of the material is continued for 30mins, with pump speed of 40rpm (90 ⁇ 10 ml/min flow rate) for both first pass and recirculation. After 30mins of recirculation, the material is recovered and collected from the first filter, OD260nm is noted and recorded. If the OD260nm is ⁇ 0.2/more preferably less than 0.1, the material is fully recovered by giving a wash of 500-600ml MQW.
- the first filter is kept aside without flushing, the collected filtrate is circulated through the second filter with a pump speed of 40rpm (90 ⁇ 10 ml/ min flow rate) and the material is recirculated with a masterflex pump speed between 150-160rpm (420 ⁇ 20 ml/ min flow rate) until the OD260nm reached ⁇ 0.2/more preferably less than 0.1.
- the recovered material kept aside. Both the filters are joined in series and a wash of 500-600ml is given to recover the filter bound PS, if any. The wash is then mixed with the recovered material.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Sustainable Development (AREA)
- Oncology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201811009693 | 2018-03-16 | ||
| IN201811009693 | 2018-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019175900A1 true WO2019175900A1 (en) | 2019-09-19 |
Family
ID=67907479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2019/050208 Ceased WO2019175900A1 (en) | 2018-03-16 | 2019-03-15 | Purification of neisseria meningitidis polysaccharides |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2019175900A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0407037A1 (en) * | 1989-06-12 | 1991-01-09 | Merck & Co. Inc. | Process for removing bacterial endotoxin from gram-negative polysaccharides |
| US20090182128A1 (en) * | 2001-06-20 | 2009-07-16 | Paolo Costantino | Capsular Polysaccharide Solubilisation and Combination Vaccines |
| WO2015128798A1 (en) * | 2014-02-25 | 2015-09-03 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | A novel downstream process for purifying polysaccharides |
| WO2017006349A1 (en) * | 2015-07-04 | 2017-01-12 | Bharat Biotech International Limited | Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides |
-
2019
- 2019-03-15 WO PCT/IN2019/050208 patent/WO2019175900A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0407037A1 (en) * | 1989-06-12 | 1991-01-09 | Merck & Co. Inc. | Process for removing bacterial endotoxin from gram-negative polysaccharides |
| US20090182128A1 (en) * | 2001-06-20 | 2009-07-16 | Paolo Costantino | Capsular Polysaccharide Solubilisation and Combination Vaccines |
| WO2015128798A1 (en) * | 2014-02-25 | 2015-09-03 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | A novel downstream process for purifying polysaccharides |
| WO2017006349A1 (en) * | 2015-07-04 | 2017-01-12 | Bharat Biotech International Limited | Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6872649B2 (en) | Shortened purification process for the production of capsular Streptococcus pneumoniae polysaccharides | |
| JP2010521972A5 (en) | ||
| US10011662B2 (en) | Downstream process for purifying polysaccharides | |
| WO2011148382A1 (en) | An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol. | |
| CN111295450A (en) | Polysaccharide Purification for Vaccine Production Using Lyase, Tangential Flow Filtration and Multimodal Chromatography | |
| WO2019175900A1 (en) | Purification of neisseria meningitidis polysaccharides | |
| WO2011145108A2 (en) | Purification of capsular polysaccharides | |
| US20260102479A1 (en) | Method for the purification of capsular polysaccharides | |
| HK1141815B (en) | Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19766798 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 19766798 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 19766798 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 10.06.2021) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 19766798 Country of ref document: EP Kind code of ref document: A1 |
